• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Angiogenesis . Interferon-alpha or -beta facilitates SARS-CoV-2 pulmonary vascular infection by inducing ACE2

tetano

Editor, Senior Moderator
Angiogenesis


. 2021 Oct 29.
doi: 10.1007/s10456-021-09823-4. Online ahead of print.
Interferon-alpha or -beta facilitates SARS-CoV-2 pulmonary vascular infection by inducing ACE2


Timothy Klouda[SUP] #[/SUP][SUP] 1 [/SUP], Yuan Hao[SUP] #[/SUP][SUP] 1 [/SUP], Hyunbum Kim[SUP] 1 [/SUP], Jiwon Kim[SUP] 1 [/SUP], Judith Olejnik[SUP] 2 3 [/SUP], Adam J Hume[SUP] 2 3 [/SUP], Sowntharya Ayyappan[SUP] 1 [/SUP], Xuechong Hong[SUP] 4 [/SUP], Juan Melero-Martin[SUP] 4 [/SUP], Yinshan Fang[SUP] 5 [/SUP], Qiong Wang[SUP] 6 [/SUP], Xiaobo Zhou[SUP] 7 [/SUP], Elke Mühlberger[SUP] 2 3 [/SUP], Hongpeng Jia[SUP] 6 [/SUP], Robert F Padera Jr[SUP] 8 [/SUP], Benjamin A Raby[SUP] 1 [/SUP], Ke Yuan[SUP] 9 [/SUP]



Affiliations

Abstract

Severe viral pneumonia caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by a hyperinflammatory state typified by elevated circulating pro-inflammatory cytokines, frequently leading to potentially lethal vascular complications including thromboembolism, disseminated intracellular coagulopathy and vasculitis. Though endothelial infection and subsequent endothelial damage have been described in patients with fatal COVID-19, the mechanism by which this occurs remains elusive, particularly given that, under naïve conditions, pulmonary endothelial cells demonstrate minimal cell surface expression of the SARS-CoV-2 binding receptor ACE2. Herein we describe SARS-CoV-2 infection of the pulmonary endothelium in postmortem lung samples from individuals who died of COVID-19, demonstrating both heterogeneous ACE2 expression and endothelial damage. In primary endothelial cell cultures, we show that SARS-CoV-2 infection is dependent on the induction of ACE2 protein expression and that this process is facilitated by type 1 interferon-alpha (IFNα) or -beta(β)-two of the main anti-viral cytokines induced in severe SARS-CoV-2 infection-but not significantly by other cytokines (including interleukin 6 and interferon γ/λ). Our findings suggest that the stereotypical anti-viral interferon response may paradoxically facilitate the propagation of COVID-19 from the respiratory epithelium to the vasculature, raising concerns regarding the use of exogenous IFNα/β in the treatment of patients with COVID-19.

Keywords: ACE2; COVID-19; Endothelial; Interferon; SARS-CoV-2.
 
Back
Top Bottom